Patient Reported Outcomes’ Influence on Pre-Launch Activities

Patient Reported Outcomes’ Influence on Pre-Launch Activities

Q1’s 4th Annual Pharma & Biotech Medical Affairs Pre-Launch Strategies Conference features an array of payer, legal and industry perspectives, including Ann Leon of CSL Behring. Learn about her experience and upcoming session below!   Can you please give a...
Mapping KOL Relationships

Mapping KOL Relationships

Q1’s 4th Annual Pharma & Biotech Medical Affairs Pre-Launch Strategies Conference taking place on April 29-30 features a mix of industry perspectives from experts, including Daniel Snyder of Revance Therapeutics, Inc. His session, “KOL Mapping: Innovative...

Boston Scientific Agrees to Pay $62.5 Million for Xlumena

Boston Scientific has agreed to a $62.5 million deal with Xlumena and its Axios line of biliary devices, putting at least another $12.5 million on the table in potential milestones, according to an article via MassDevice.com.  The move establishes both Boston...